EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Bioequivalence Study of a New Generic Fixed-Dose Combination of Sitagliptin (100 mg) and Glimepiride (2 mg) in Healthy Adult Volunteers under Fasting Condition

Prashant Kumthekar, Mihir Upadhyay, Koripalli S. Reddy, Sambasiva R. Puram, Basava S. Nallamekala

Chronicle of Diabetes Research and Practice · 2025

DOI: 10.4103/cdrp.cdrp_10_25 ↗
AbstractBibliografische Angaben

Abstract

Introduction: The present study evaluated the bioequivalence of a fixed-dose combination (FDC) of sitagliptin and glimepiride with the originator reference product. Methods: This was an open-label, randomized, two-period, cross-over, single-dose, comparative bioequivalence study. Participants were randomized to receive either test product (sitagliptin 100 mg + glimepiride 2 mg) or reference products (sitagliptin 100 mg and glimepiride 2 mg) under the fasting condition, with a 7-day washout period. The primary outcome was the assessment of bioequivalence with primary pharmacokinetic (PK) parameters, maximum measured plasma concentration (C max ), and area under the plasma concentration (area under the curve [AUC])-time curve from time 0 to last measurable concentration (AUC 0–t ). Secondary PK parameters (AUC 0–inf , T max , T 1/2 , and AUC extrapolation ) of sitagliptin and glimepiride were recorded for both products. Adverse events were observed. Results: Of 24 randomized participants, 23 completed the study and had a mean (standard deviation) age of 33.61 (6.16) years. The 90% CI of the geometric mean of T/R ratios for primary PK parameters, AUC 0–t and C max , were 87.04–99.86 and 93.74%–100.09% for sitagliptin, while 86.86–107.35 and 91.01%–105.27% for glimepiride; and were within predefined bioequivalence acceptable range (80.00%–125.00%). Secondary PK parameters, AUC 0–inf and T max of sitagliptin were 3780.51 h*ng/mL and 2.49 h and glimepiride were 925.84 h*ng/mL and 6.96 h, respectively. Conclusion: The new generic FDC sitagliptin phosphate (sitagliptin 100 mg) + glimepiride (2 mg) demonstrated bioequivalence to originator reference products with similar safety and tolerability among healthy adult participants in fasting conditions.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →